LIMN is Liminatus Pharma, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $4.23. Market cap: $6M.
Stock snapshot
| Price | $4.23 |
| Market cap | $6M |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About LIMN
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Related non-dividend companies
Other non-dividend stocks investors research alongside LIMN. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is LIMN's current stock price?
LIMN (Liminatus Pharma, Inc.) is currently trading at $4.23.
Does LIMN pay a dividend?
LIMN (Liminatus Pharma, Inc.) does not currently pay a regular dividend.
Track LIMN in DiviDrip
Add LIMN to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search LIMN and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-08-30. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.